Business Context and Reporting Period
Company: Surgery Partners, Inc. (SGRY)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: The Company owns and operates a national network of 162 surgical facilities (143 Ambulatory Surgery Centers and 19 surgical hospitals) across 30 states, primarily in partnership with physicians. As of June 30, 2025, the Company consolidated 115 facilities for financial reporting purposes.
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Revenues | $826.2 | $762.1 | $1,602.2 | $1,479.5 |
| Operating Income | $111.7 | $84.8 | $173.6 | $160.8 |
| Net Income (Consolidated) | $44.9 | $28.4 | $44.6 | $52.7 |
| Net Loss Attributable to Surgery Partners | $(2.5) | $(15.5) | $(40.2) | $(27.9) |
| Adjusted EBITDA | $129.0 | $118.3 | $232.9 | $215.8 |
| Cash and Cash Equivalents | $250.1 | $213.5 | $250.1 | $213.5 |
| Total Debt (Carrying Amount) | $3,575.2 | $3,370.3 | $3,575.2 | $3,370.3 |
| Operating Cash Flow (YTD) | $87.3 | $123.5 | $87.3 | $123.5 |
Liquidity: As of June 30, 2025, the Company had $250.1 million in cash and cash equivalents and $394.9 million of availability on its senior secured revolving credit facility.
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 revenues increased 8.3% year-over-year, driven by a 5.1% increase in days-adjusted same-facility revenues (comprising a 3.4% increase in case volume and 1.6% increase in revenue per case) and net acquisitions.
- Profitability: Operating income improved significantly to $111.7 million in Q2 2025 from $84.8 million in Q2 2024. Adjusted EBITDA rose 9.0% to $129.0 million.
- Net Loss Reduction: Net loss attributable to Surgery Partners, Inc. narrowed to $2.5 million in Q2 2025 compared to $15.5 million in Q2 2024, primarily due to higher operating income and a tax benefit.
- Interest Expense: Net interest expense increased to $67.9 million in Q2 2025 from $51.5 million in Q2 2024, driven by increased borrowings on the Revolver and the maturity of interest rate swaps in Q1 2025.
- Acquisitions and Disposals: In the first six months of 2025, the Company acquired controlling interests in four surgical facilities and two physician practices for $48.0 million. It also sold controlling interests in two facilities for $42.4 million, recognizing a $6.0 million gain.
Guidance, Outlook, and Risks
Management Commentary: Management continues to focus on improving same-facility performance, selectively acquiring established facilities, and pursuing portfolio management initiatives. The Company believes its cash flows, available cash, and revolver capacity are adequate to meet short-term and long-term liquidity needs.
Legislative Impact: On July 4, 2025, Congress passed the "One Big Beautiful Bill Act" (OBBBA), introducing changes to Medicare, Medicaid, and the Affordable Care Act. While projected to reduce overall healthcare spending and increase regulatory burdens, management does not expect a material impact on financial statements. The OBBBA also made 100% bonus depreciation permanent.
Risks and Contingencies:
- Interest Rate Risk: The Company utilizes interest rate swaps and caps to manage exposure. Several swaps matured in March 2025, replaced by deferred premium caps.
- Valuation Allowance: The Company maintains a full valuation allowance on net deferred tax assets due to a cumulative three-year pre-tax loss position.
- Legal Proceedings: The Company is subject to ordinary course claims (patient treatment, employment, etc.) but is not aware of any proceedings reasonably possible to have a material adverse effect.
Investor Verification Checklist
- Non-Controlling Interests (NCI): Verify the impact of NCI on net income, which reduced consolidated net income by $47.4 million in Q2 2025, resulting in a net loss attributable to the parent company despite positive consolidated earnings.
- Debt Servicing: Review the increase in net interest expense ($67.9M in Q2 2025) and the maturity of hedging instruments to assess future cash flow requirements.
- Same-Facility Growth: Confirm the sustainability of the 5.1% same-facility revenue growth, specifically the split between volume (3.4%) and price (1.6%).
- Legislative Changes: Monitor the implementation details of the OBBBA passed in July 2025 for potential long-term reimbursement impacts not yet reflected in the Q2 tax provision.
- Working Capital: Note the decrease in operating cash flow ($87.3M YTD 2025 vs. $123.5M YTD 2024) driven by higher interest payments and working capital timing.